Back to search
FDAFDA · Food and drugs·Recall number D-0551-2025

Lorazepam Injection, USP, 2 mg/mL, 25 x 1mL vials/carton, Rx Only, Manufactured by: Hikma Berkeley Heights, NJ 07922, NDC# 0641-6044-25

Published August 6, 2025 · Recall initiated: July 22, 2025

Summary

FDA records drug Class II recall D-0551-2025, published August 6, 2025 and initiated July 22, 2025. Recalling firm: Hikma Pharmaceuticals USA Inc.; Status: Ongoing; Reported quantity: 382,775 1mL vials; Lot: Lot # K24118, exp. date 10/31/2026. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds

What to do

Voluntary: Firm initiated · Letter

Get an email if LORAZEPAM has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
LORAZEPAM
Manufacturer
Hikma Pharmaceuticals USA Inc.
Distributor
Distributed Nationwide in the USA
Lot
Lot # K24118, exp. date 10/31/2026
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Lorazepam Injection, USP, 2 mg/mL, 25 x 1mL vials/carton, Rx Only, Manufactured by: Hikma Berkeley Heights, NJ 07922, NDC# 0641-6044-25 recalled?

Yes. FDA published recall D-0551-2025 on August 6, 2025. Reported hazard: Failed Impurities/Degradation Specifications: An out-of-Specification for total related compounds

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: LORAZEPAM.